Over-the-Counter Flonase Allergy Relief Approved
The FDA has approved over-the-counter Flonase Allergy Relief, or fluticasone propionate 50 mcg nasal spray, for treatment of hay fever or upper respiratory allergies, its maker GlaxoSmithKline announced. (Source: WebMD Health)
Source: WebMD Health - July 28, 2014 Category: Consumer Health News Source Type: news
FDA Clears OTC Flonase Nasal Spray for Allergy Relief FDA Clears OTC Flonase Nasal Spray for Allergy Relief
Fluticasone propionate 50 mcg nasal spray is the first and only OTC nasal spray for hay fever and upper respiratory allergies. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Flonase Goes OTC
(MedPage Today) -- The FDA has approved over-the-counter sales for Flonase (fluticasone propionate), the nasal spray for allergies, its manufacturer said. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - July 25, 2014 Category: Allergy & Immunology Source Type: news
High-dose fluticasone effective against eosinophilic esophagitis, study shows
High doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis, a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils, research shows. However, some trial participants in the study did not respond to fluticasone even after six months of high-dose treatments, providing evidence that certain people with eosinophilic esophagitis are steroid-resistant. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 18, 2014 Category: Science Source Type: news
High-dose fluticasone effective against eosinophilic esophagitis
(NIH/National Institute of Allergy and Infectious Diseases) Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis, a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils. However, some trial participants did not respond to fluticasone even after six months of high-dose treatments, providing evidence that certain people with eosinophilic esophagitis are steroid-resistant. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 18, 2014 Category: Global & Universal Source Type: news
Steroid asthma inhalers restrict children’s growth
Conclusion
This systematic review has found that inhaled corticosteroid drugs suppress growth in children with persistent asthma who take them regularly, during the first year of treatment.
This was high quality, well-conducted research, and its conclusions are likely to be reliable.
While the results are likely to worry parents, uncontrolled asthma can restrict a child’s activities and lower their quality of life. In severe cases, it can lead to life-threatening asthma attacks.
Even low-grade, persistent symptoms can lead to fatigue, underperformance or absence from school as well as psychological problems, includ...
Source: NHS News Feed - July 17, 2014 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news
Mundipharma commences COPD trial
Mundipharma Research Limited (Mundipharma) has announced a major milestone in the development programme of flutiform® (fluticasone propionate/formoterol fumarate) for the treatment of Chronic Obstructive Pulmonary Disease (COPD) with the commencement of a key clinical trial. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 19, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Industry News Respiratory Source Type: news
FDA Updates Lopinavir/Ritonavir (Kaletra) Labeling to Include New Drug Interaction Information
"On January 17, 2013, FDA approved revisions to the Kaletra (lopinavir/ritonavir) labels to include new drug interaction information. The following updates were included.
"Anticoagulants: Rivaroxaban. Avoid concomitant use of rivaroxaban and Kaletra. Coadministration of Kaletra and rivaroxaban is expected to result in increased exposure of rivaroxaban which may led to risk of increased bleeding
"Anticonvulsants: Lamotrigine and valproate. Coadministration of Kaletra and lamotrigine or valproate may decrease the exposure of lamotrigine or valproate. A dose increase of the lamotrigine or valproate may be nee...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 22, 2013 Category: Infectious Diseases Source Type: news
MHRA consults on reclassification of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (fluticasone propionate) from P to GSL
Source: MHRA
Area: News
Consultation ARM 83 seeks views on the reclassification of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (fluticasone propionate) from Pharmacy (P) to General Sales List (GSL). The Reclassification Summary and patient information leaflet as provided by the applicant company are available via the link below.
The closing date for receipt of comments is 1 Feb 2013. (Source: NeLM - News)
Source: NeLM - News - January 8, 2013 Category: Drugs & Pharmacology Source Type: news
